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Calcitonin in the Treatment 

of Paget's Disease of Bone 

This study was undertakent at the request of 
Pharmacy & Therapeutics Committee, St. 
Luke's Hospital. 
INTRODUCTION 
A retrospective survey was undertaken to 
evaluate prescribing habits of calcitonin in 
Paget's disease of bone, as well as to assess 
its effectiveness. 
MATERIALS AND 

METHODS 

The material presented is based on a review 
of the case histories and radiographs of 33 
patients suffering from Paget's disease and 
receiving calcitonin therapy. The diagnosis 
of Paget's disease was made on the basis of 
an elevated level of serum alkaline phospha· 
tase (S.A.P.) in association with typical 
radiological abnormalities (areas of osteoly­
sis alternating with osteosclerosis, loss of 
normal tr~becular bone pattern, with or 
without bone distortion). (Fig. 1, 2) The 
patients involved were 28 males, age range 
41 to 81 (mean 60) years and 5 females, age 
range 47-68 (mean 62.4) years at the time of 
diagnosis. 5 of the male patients were below 
50 years of age. Except for one, all patients . 
were symptomatic, 9 having low back pain, 
8 hip pain, 5 knee pain, 4 diminished 
hearing. Other complaints included lower 
limb weakness, paraesthesiae and cramps 
in the legs, swelling in the forearm, swelling 
in the leg and pain in one shoulder (one 
patient each). From the radiological data 
available, the parts of the skeleton involved 
were as follows: pelvis (27 patients), femur 
(22 patients), skull (13 patients), lumbar 
spine (17 patients), dorsal spine (7 patients), 
radius (1 patient), humerus (1 patient). 
Other x-ray changes noted included degen­
erative joint disease (in hips, knees, spine) as 
well as diffuse idiopathic skeletal hyper­
ostosis (D.I.S.H.) in 4 patients. 
All patients received calcitonin therapy. No 
single dosage schedule was followed. Some 
patients were started on daily injections (50­
200 U) and the maintenance dose varied 
from one injection (50-200 U) monthly to 3 
injections (50-100) per week. Three patients 
experienced side effects - flushing, nausea, 
vomiting; in one patient they became severe 
enough that treatment had to be stopped. 
Duration of treatment varied from a few 
months (5 ofthe 33 patients were started on 
treatment in the second halfof 1988; so there 
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was not enough time for a full evaluation) up 
to 7 years. Several patients had other forms 
of treatment - 9 had calcium supplements, 
11 had nonsteroidal anti-inflammatory 
drugs and/ or other analgesics and 16 had 
anabolic steroids (Primobolan injections). 
Ofthe 33 patients 6 felt better in so for as the 
pain was concerned: one felt significantly 
better within 4 weeks of starting calcitonin 
injections; 2 had a moderate improvement, 
while 3 had slight improvement. The other 
patients did not seem to benefit: in 
particular none of the patients with reduced 
hearing showed any improvement. 
The dnly biochemical parameter examined 
was serum alkaline phosphatase: there was 
not enough time for follow-up levels of 
alkaline phosphatase to be measured on the 
five patients started on calcitonin after the 
middle of1988. Ofthe remaining 28 patients 
there was no drop in serum alkaline 
phosphatase levels in 19 patients. In the 
other 9 a significant drop ofthe enzyme was 
noted, arbitrarily taken to mean a drop of 
40% or more from initial levels. Of these 9 
patients, 1 was receiving both calcitonin 
and disodium editronate (Didronel), 3 had a 
transient drop of serum ·alkaline phospha­
tase within 6-9 months ofstarting treatment 
which then returned to the initial high 
levels, whereas 5 patients had a sustained 
drop in serum alkaline phosphatase level. 4 
patients were treated with disodium editron­
ate after no effect had been noted with 
calcitonin: they all experienced a significant 
drop in serum alkaline phosphatase levels. 
Only two of the patients with a reduction in 
the level of alkaline phosphatase had 
symptomatic improvement; in the remaining 
11 patients, despite a drop in the enzyme 
level, no change in symptomatology was. 
noted. Conversely, 4 patients who felt better 
did not show any drop in alkaline phosphat­
ase level. 
COMMENTS 
Several problems were encountered in 
carrying out this survey, the main one being 
poor clinical documentation, e.g. lack of 
characterisation ofpain as to whether it was 
primarily bone pain or pain due to 
coincidentally associated osteoarthritic 
changes (and these are particularly common 
in the age group under consideration) as 
well as poor follow-up information regarding 
changes in symptomatology. The only 
biochemical parameter that can be measured 
locally is the serum alkaline phosphatase: 
this only measures one aspect ofthe disease 
(osteoblastic activity). The other facet of the 
disease, osteoclastic activity - now 
considered to be the initial pathology of the 
disease - can be measured by urinary 
hydroxyproline estimation. Besides, the 
true extent of the disease can only be 
properly assessed by nuclear bone scanning; 
this technique can also be used in the follow­
up of patients to assess disease activity. 
Conventional radiography is not sensitive 
enough for this, as radiologically abnormal 
bone is not necessarily the site of active 
pagetic bone. 
In 	general, calcitonin seemed relatively 
ineffective in the majority of patients with 
Paget's disease in whom it was used. This 
may have been due partly to poor patient 
selection - e.g. ascribing pain to be due to 
bone involvement by Paget's disease rather 
than to associated, or secondary, degen­
erative joint disease or nerve compression. 
None of the 4 patients with hearing 
impairment showed any improvement on 
calcitonin therapy - quite possible because 
treatment was started too late. The small 
number of patients showing a significant 
drop in serum alkaline phosphatase levels 
while on calcitonin, however, speaks out for 
the relative lack of efficacy of the drug in 
this group of patients. An estimate of the 
cost involved was calculated in 23 patients 
- where the average consumption was 
known: this worked out at LMll,OOO 
(average LM484 per patient). This is a very 
high price to pay for the comparatively little 
benefit obtained. The fact that 4 patients 
showed a significant drop in serum alkaline 
phosphatase levels when treated with 
disodium editronate after having shown no 
effect with calcitonin is in keeping with the 
current view that diphosphonates are more 
effective than calcitonin in controlling 
activity in Paget's disease. 
The disparity between clinical and bio­
chemical improvement noted in several of 
the patients could have been due to various 
causes: 
a. 	 poor patient selection - i.e. the pain not 
being due to Paget's disease itself but 
due to, for example, associated osteo­
arthritis. Concomitant nonsteroidal anti-
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inflammatory therapy may relieve pain 
with having any effect on the underly­
ing disease. Alternatively, pagetic 
activity may be reduced, but symptoms 
due to mechanical problems (such as 
degenerative joint disease, nerve com­
pression) persist. 
b. 	 a nonspecific analgesic effect from 
calcitonin itself may operate: calcitonin 
is also recommended for other painful 
bone conditions, such as acute painful 
crises in osteoporosis as well as in 
metastatic bone disease. 
c. 	 one patient who showed a significant 
improvement in back pain after 4 weeks 
of calcitonin therapy would have prob­
ably shown a drop in alkaline phosphat­
ase level had he been followed up for a 
longer period. Most pagetic patients 
who respond to calcitonin, in fact, show 
a clinical response much before a 
biochemical one. 
d. 	 a placebo effect cannot be entirely 
ruled out. 
CONCLUSIONS 
Certain broad guidelines should be followed 
by physicians and orthopaedic surgeons 
who are involved in the management of 
patients with Paget's disease of bone. In 
several instances the disease is entirely 
asymptomatic, and discovered only as an 
incidental finding: in most such patients no 
specific therapy is generally indicated. 
Abnormal biochemistry is NOT in itself an 
indication for treatment. 
Major indications for treatment should 
include: 
1. 	 bone pain 
2. 	 prior to orthopaedic surgery, to reduce 
bone vascularity 
3. 	 neurologic involvement 
4. 	 high output congestive cardiac failure 
- a situation most likely to be found in 
patients with extensive Paget's disease 
and with preexisting heart disease 
5. 	 bone fractures 
6. 	 treatment or prevention of hyper­
calcaemia resulting from immobil­
isation. 
Specific therapy may be indicated as a 
prophylactic measure especially in young 
individuals in certain situations, such as: 
1. 	 involvement of the base of the skull 
2. 	 involvement of the spine - especially 
above L2 
3. 	 asymptomatic involvement in a weight­
bearing bone. 
In general , calcitonin should no longer be 
considered as the first line specific agent for 
Paget's disease of bone. If it is used, and no 
pain relief is apparent within 8 weeks, then 
it should be stopped. Ifpain is relieved , itcan 
be continued for a year and then stopped. 
Rebound is inevitable with time, but 
another course can be successful. Recurrent 
and prolonged use ofcalcitonin will result in 
the production of antibodies which further 
reduced its effectiveness. 
Diphosphonates are considered more effec­
tive than calcitonin . They are certainly not 
the final answer, and disodium editronate 
(Didronel), the only diphosphonate currently 
available locally, suffers from several major 
disadvantages - it is poorly absorbed; it 
may cause on increase in bone pain at the 
start of treatment; and - most important of 
all- it can produce osteomalacia when used 
for prolonged periods of time. For this 
reason, it is generally recommended for the 
drug to be given in a dose of 5 mg/ kg body 
weight for a period of 6 months. A 
favourable response is reported in over 65'),h 
of patients, and the benefit often lasts 
several years after the drug is stopped. 
Following a relapse, control can be regained 
by a further 6 month course. It is not a cheap 
drug, and an average course (400 mg/ day 
for 6 months) would cost just over LMlOO. 
New diphosphonates have been developed 
which do not cause osteomalacia. One 
particular preparation, disodium amino­
hydroxy-propylidene biphosphonate -
AHPrBP - (Aredia, Ciba-Geigy) has been 
shown to exert a significant effect in 
patients with Paget's disease of bone after 
one single intravenous injection, with a 
significant benefit still being demonstrable 
one year after treatment.' 
Patients with severe and unresponsive 
disease may occasionally benefit from 
combined therapy with calcitonin and a 
diphosphonate. 
Severe Paget's Disease of 
1. TIBIA 
2. PELVIS 
Except for a single report that a combination 
oforal calcium and a thiazide diuretic (in an 
attempt to stimulate endogenous calcitonin 
secretion) caused a modest drop in alkaline 
phosphatase activity and urinary hydroxy­
proline excretion,2 there is no evidence that 
other forms of therapy such as anabolic 
steroids confer any benefit to patients with 
Paget's disease of bone, and their use ought 
to be actively discouraged. Pain due to 
osteoarthritis can very often be managed by 
analgesia, anti-inflammatory drugs and 
physiotherapy. 
Surgery may be needed in certain situations 
- e.g. orthopaedic surgery for patients who 
develop severe degenerative arthritis of the 
hip, where a hip replacement can result in 
pain-free normal ambulation, or tibial 
osteotomy for severe bowing of the tibia 
which may correct the deformity and allow 
much improved ambulation; neurosurgery 
for patients with nerve compression from 
vertebral involvement or for patients with 
severe basilar impression and neurologic 
deficit. All such surgery should be done after 
treatment with a drug which suppresses the 
activity of the disease to prevent excessive 
haemorrhage and postoperative hyper­
calcaemia. 
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